RNAi therapeutics company RXi Pharmaceuticals has appointed Robert Bitterman and Keith Brownlie to its board of directors. Mr Bitterman currently serves as president and CEO of Cutanea Life Sciences, a wholly owned subsidiary of Maruho Company. Mr Brownlie joins RXi following a 36-year career at Ernst & Young. For the last 20 years before his retirement in 2010, he was Metro New York Area Life Sciences Industry Leader at the company. Mr Brownlie also serves on the boards of Epicept and Soligenix.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
